Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection

OBJECTIVES: Ridinilazole (SMT19969) is a narrow-spectrum, non-absorbable antimicrobial with activity against Clostridium difficile undergoing clinical trials. The purpose of this study was to assess the pharmacological activity of ridinilazole and assess the effects on cell morphology. METHODS: Anti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Antimicrob Chemother
Egile Nagusiak: Bassères, Eugénie, Endres, Bradley T., Khaleduzzaman, Mohammed, Miraftabi, Faranak, Alam, M. Jahangir, Vickers, Richard J., Garey, Kevin W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2016
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4830417/
https://ncbi.nlm.nih.gov/pubmed/26895772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkv498
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak